1. Academic Validation
  2. Signaling Mechanism of Cuproptosis Activating cGAS-STING Immune Pathway

Signaling Mechanism of Cuproptosis Activating cGAS-STING Immune Pathway

  • JACS Au. 2024 Sep 20;4(10):3988-3999. doi: 10.1021/jacsau.4c00712.
Chengyuan Zhu 1 Jialiang Li 1 Wanying Sun 1 Desheng Li 1 Yiliang Wang 1 Xing-Can Shen 1
Affiliations

Affiliation

  • 1 State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, China.
Abstract

Copper-mediated programmed cell death, which influences the regulation of tumor progression, is an effective approach for antitumor molecular therapy. Unlike Apoptosis, copper complex-induced Cuproptosis by lipid-acylated protein aggregation triggers the mitochondrial proteotoxic stress response, which could be associated with immunomodulation. However, it remains a great challenge to understand the distinctive molecular mechanisms that presumably activate immunity by Cuproptosis. Here, the new nonlabeling fluorescent molecular tools of Cu-DPPZ-Py+ and Cu-DPPZ-Ph are synthesized and used to investigate the differential immune signaling mechanisms induced by copper-mediated Cuproptosis or Apoptosis. With Cu-DPPZ-Py+ and Cu-Elesclomol, there is strong evidence that the triggering Cuproptosis significantly drives mitochondrial DNA (mtDNA) release to activate innate immunity via cyclic GMP-AMP synthase-stimulation of interferon genes (cGAS-STING), which can improve T cell antitumor immunity in vivo. By contrast, it is observed that Cu-DPPZ-Ph treated tumor cells could release intracellular Caspase-3, resulting in apoptosis-associated immunosuppression. This study supports insights into how Cuproptosis bridges cGAS-STING immune pathways, contributing to the development of cuproptosis-based antitumor immunotherapy.

Figures
Products
Inhibitors & Agonists